Initial serum tumor marker change predicts progression-free and overall survival in immune checkpoint blockade treated non-small cell lung cancer

被引：0
|
作者：
Lang, David [1 ]
Horner, Andreas [1 ]
Brehm, Elmar [1 ]
Romain, Silas [2 ]
Kaiser, Bernhard [1 ]
Lamprecht, Bernd [1 ]
机构：
[1] Kepler Univ Hosp, Dept Pulmonol, Linz, Austria
[2] Johannes Kepler Univ Linz, Fac Med, Linz, Austria
来源：
WIENER KLINISCHE WOCHENSCHRIFT | 2018年 / 130卷 / 19-20期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P44
引用
收藏
页码：618 / 619
页数：2
相关论文
共 50 条
  • [21] Pretreatment SUVmax predicts progression-free survival in early-stage non-small cell lung cancer treated with stereotactic body radiation therapy
    Horne, Zachary D.
    Clump, David A.
    Vargo, John A.
    Shah, Samir
    Beriwal, Sushil
    Burton, Steven A.
    Quinn, Annette E.
    Schuchert, Matthew J.
    Landreneau, Rodney J.
    Christie, Neil A.
    Luketich, James D.
    Heron, Dwight E.
    RADIATION ONCOLOGY, 2014, 9
  • [22] DSPP is a serum marker for disease progression and patient survival in non-small cell lung cancer
    Xue, J.
    Fedarko, N.
    JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 2021, 69 : S289 - S290
  • [23] Time to Progression as a Surrogate Marker for Overall Survival in Patients with Advanced Non-small Cell Lung Cancer
    Hotta, Katsuyuki
    Fujiwara, Yoshiro
    Matsuo, Keitaro
    Kiura, Kutsuyuki
    Takigawa, Nagio
    Tabata, Masahira
    Tanimoto, Mitsune
    JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (03) : 311 - 317
  • [24] Excision repair cross-complementation group 1 predicts progression-free and overall survival in non-small cell lung cancer patients treated with platinum-based chemotherapy
    Azuma, Koichi
    Komohara, Yoshihiro
    Sasada, Tetsuro
    Terazaki, Yasuhiro
    Ikeda, Jiro
    Hoshino, Tomoaki
    Itoh, Kyogo
    Yamada, Akira
    Aizawa, Hisamichi
    CANCER SCIENCE, 2007, 98 (09) : 1336 - 1343
  • [25] Number of ALK-amplified circulating tumor cells predicts progression-free survival in ALK-rearranged non-small cell lung cancer patients treated by crizotinib
    Pailler, Emma
    Oulhen, Marianne
    Ross, Kirsty
    Billiot, Fanny
    Auger, Nathalie
    Borger, Isabelle
    NgoCamus, Maud
    Remon-Masip, Jordi
    Planchard, David
    Soria, Jean-Charles
    Besse, Benjamin
    Farace, Francoise
    CANCER RESEARCH, 2016, 76
  • [26] Tumor Mutational Burden Predicts Progression-Free Survival and Local-Regional Control in Locally Advanced Non-Small Cell Lung Cancer Patients Treated with Chemoradiation and Durvalumab
    Shaverdian, N.
    Shepherd, A. F.
    Offin, M.
    Gelblum, D.
    Wu, A. J.
    Simone, C. B., II
    Schoenfeld, A. J.
    Jones, D.
    Rimner, A.
    Chaft, J.
    Riaz, N.
    Gomez, D. R.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2022, 114 (03): : E390 - E391
  • [27] THE SUM OF TUMOR SIZE PREDICTS THE EFFICACY OF IMMUNE CHECKPOINT INHIBITORS IN NON-SMALL CELL LUNG CANCER
    Shiraishi, Yusuke
    Marumo, Satoshi
    Amimoto, Hisanori
    Yamaki, Haruka
    Shirata, Masahiro
    Imoto, Takamitsu
    Kitajima, Takamasa
    Inoue, Daiki
    Katayama, Yuko
    Fukui, Motonari
    RESPIROLOGY, 2018, 23 : 289 - 289
  • [28] Prediction of brain metastases progression and overall survival in patients with metastatic non-small cell lung cancer treated by immune checkpoint inhibitors using a radiomic model
    Henon, Clemence
    Hendriks, Lizza
    Carre, Alexandre
    Mezquita, Laura
    Reuze, Sylvain
    Ammari, Samy
    Aldea, Mihaela
    Robert, Charlotte
    Le Pechoux, Cecile
    Audigier-Valette, Clarisse
    Mazieres, Julien
    Lefebvre, Corentin
    Rabeau, Audrey
    Duchemann, Boris
    Botticella, Angela
    Planchard, David
    Deutsch, Eric
    Besse, Benjamin
    Sun, Roger
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [29] CT SCAN NORMALIZATION TO IMPROVE RADIOMICS GENERALIZABILITY AND ASSESS PROGRESSION-FREE SURVIVAL IN PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER TREATED WITH IMMUNE CHECKPOINT INHIBITORS: A MULTICENTRIC STUDY
    Tonneau, Marion
    Phan, Kim
    Low-Kam, Cecile
    Dutil, Francis
    Kazandjian, Suzanne
    Vanderweyen, Davy
    Panasci, Justin
    Malo, Julie
    Coulombe, Francois
    Elkrief, Arielle
    Belkaid, Wiam
    Di Jorio, Lisa
    Orain, Michele
    Bouchard, Nicole
    Muanza, Thierry
    Kafi, Kam
    Chandelier, Florent
    Joubert, Philippe
    Routy, Bertrand
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 : A1350 - A1350
  • [30] Effect of antimicrobial therapy on progression-free survival of patients with non-small cell lung cancer receiving checkpoint inhibitor- and chemotherapy
    Uhlenbruch, Mark
    Kruger, Stefan
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2022, 148 (08) : 2079 - 2082
12345